Ftx-6058 thalassemia
WebNov 23, 2024 · 113.Hemoglobinopathies, Excluding Thalassemia: Basic and Translational. Measuring H3K27me3 Reduction after in-Vivo Administration of Ftx-6058; A Potent Polycomb Repressive Complex 2 (PRC2) Inhibitor ... FTX-6058 is an investigational drug for the treatment of Sickle Cell Disease (SCD). The molecule is a selective and potent … WebFTX-6058 demonstrated a superior pharmacological profile relative to hydroxyurea and other small molecule compounds whose putative mechanism of action is to induce HbF. FTX-6058 treatment resulted in robust target engagement and subsequent elevation of the endogenous mouse Hbb-bh1 mRNA in wildtype CD-1 mice and, importantly, also …
Ftx-6058 thalassemia
Did you know?
WebDec 6, 2024 · FTX-6058 is an investigational oral HbF inducer that is being developed for the treatment of sickle cell disease and other hemoglobinopathies, such as beta-thalassemia. WebApr 11, 2024 · FTX-6058 has previously been well tolerated in patients with sickle cell who were exposed for up to three months, with no drug-related adverse events, Fulcrum said. The trial was to enroll up to 40 participants, according to an entry in the U.S. National Library of Medicine’s clinical trials database.
WebOct 27, 2024 · Phase 1 Trial of Oral FTX-6058 to Promote Fetal Hemoglobin Set to Open. FTX-6058, an investigational oral treatment being developed by Fulcrum Therapeutics for sickle cell disease (SCD) and beta-thalassemia, is entering a Phase 1 clinical trial in healthy volunteers, the company announced. The trial ( NCT04586985 ), not yet enrolling, aims …
WebNov 5, 2024 · Preclinical studies using a variety of in vitro assays have demonstrated the potential of FTX-6058 as a clinical development candidate for potential treatment of … WebJun 10, 2024 · Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
WebMar 17, 2024 · FTX 6058 Alternative Names: FTX HbF; FTX-6058 Latest Information Update: 17 Mar 2024. Price : $50 * Buy Profile. Adis is an information provider. ... 01 Mar 2024 Fulcrum Therapeutics withdraws IND for FTX 6058 for Beta-thalassemia, as of March 2024 ; 23 Feb 2024 Fulcrum puts clinical hold a phase-I for Sickle cell anaemia in USA …
WebSep 7, 2024 · FTX-6058, an investigational oral treatment being developed by Fulcrum Therapeutics for sickle cell disease (SCD) and beta-thalassemia, was found to be … oakcroft garageWebMar 10, 2024 · FTX-6058 is a potent and orally available small molecule inhibitor of the Embryonic Ectoderm Development (EED), a subunit of the PRC2 protein complex. In preclinical studies, Fulcrum has shown that using FTX-6058 to target EED induces an increase in fetal hemoglobin. In December 2024, the FDA granted the candidate Fast … maid service northwest indianaWebNov 4, 2024 · Poster Title: In vivo characterization of FTX-6058, a novel small molecule fetal hemoglobin inducer for sickle cell disease Presenter: Keqiang Xie, Ph.D., Senior Scientist at Fulcrum Therapeutics Session Name: 113. Hemoglobinopathies, Excluding Thalassemia—New Genetic Approaches to Sickle Cell Disease: Poster I Date and Time: … maid service newtown square paWebApr 9, 2024 · FTX-6058 is a highly potent orally bioavailable small molecule EED inhibitor for the potential treatment of select hemoglobinopathies, including sickle cell disease and β-thalassemia. The validation of EED as a fetal hemoglobin (HbF) inducer target for sickle cell disease was conducted using FulcrumSeek, Fulcrum’s proprietary product engine. maid service nhWebApr 16, 2024 · The company also is looking to explore the use of FTX-6058 in patients with beta-thalassemia to supplement their reduced hemoglobin production. The pharmacologic profile of FTX-6058 indicates that the drug has the potential to be administered as a once-a-day oral formulation, Dr. Efremov stated. Both the preclinical PK [pharmacokinetic] data ... maid service north hollywoodWebDec 6, 2024 · FTX-6058 is an investigational oral HbF inducer that is being developed for the treatment of sickle cell disease and other hemoglobinopathies, such as beta-thalassemia. Data from the 20mg and 30mg dose cohorts demonstrated a mean 5.6-fold induction and a mean 6.2-fold induction in HBG mRNA, respectively, at day 14. maid service oaklandWebFTX-6058 hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). FTX-6058 hydrochloride can induce HbF protein expression in cell and murine models. FTX-6058 hydrochloride can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia[1][2]. maid service newton ma